Pharmaceutical services and technology industry veteran joins Harpula to help build new company and market demand through acquisitions, organic growth and business development

Raleigh, NC – April 26, 2024

Harpula is pleased to announce the appointment of Jack Shannon as the company's new Chief Commercial Officer. In his new role, Jack will be responsible for driving commercial growth across all sales and marketing activities, as well as helping to develop and execute the company’s M&A strategies. He will work closely with the executive team to develop and execute on strategic plans that will enable Harpula to achieve its goals and objectives.

"Jack is a highly respected leader in the clinical trial and life sciences industry, and we are thrilled to have him join up again with Mary Mattes and I at Harpula," said Steve Powell, CEO. " I am confident that Jack's expertise, strategic vision, and passion for innovation will be invaluable to Harpula as we continue to build out our company, focused on improving the delivery of clinical trials to Sponsors, Sites and most importantly Patients."

Jack brings over 20 years of experience in the pharmaceutical and biotech industries, with a proven track record of developing and executing successful commercial strategies, launching new products, and building high-performing sales and marketing teams. He has held leadership positions at several global CROs, including PRA Health Sciences, IQVIA (Quintiles), Chiltern, and Synteract, where he played key roles in driving business growth and expanding market share. Most recently, Jack was the Chief Commercial Officer for Virb. Jack will be based in Harpula’s Raleigh, NC office.

"I am excited to join the talented team at Harpula and lead the company's commercial growth efforts," said Jack. "Harpula’s mission to drive patient access and improve on the patient experience through innovative technologies is not only necessary to help further clinical research, but also to increase patient access across all therapeutic areas and populations.”

About Harpula

Harpula’s mission is to foster the growth of next generation technologies and services for clinical trials. Our goal is to build a company that excels in today’s clinical trial landscape of personalized medicine, multiple trial modalities, and increased patient centricity. Harpula is backed by Chicago-based private equity firm GTCR, with 40+ years of experience and more than $26 billion under management. GTCR brings their pioneering The Leaders Strategy™ and core domain experience in healthcare and pharma-tech to bear for Harpula, with their focus on investing in transformative growth in their portfolio companies.

For more information, visit our website at harpula.com. and follow us on LinkedIn.